All Seven Patients Treated with BEAM-101 Achieved Hemoglobin F (HbF) Induction of >60%, Hemoglobin S (HbS) Reduction to 60%, a decrease in hemoglobin S to
Beam Therapeutics Announces New Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at American Society of Hematology (ASH) Annual Meeting
On 6ix: 6ix.com/news/beam-therapeutics-announces-new-data-beacon-phase-1-2-clinical-trial-beam-101-sickle
Story so far
- Beam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle Cell Disease and ESCAPE Non-human Primate Data, at American Society of Hematology (ASH) Annual Meeting
- Beam Therapeutics Reports Data Highlighting Optimized Manufacturing Process for BEAM-101, an Investigational Base Editing Therapeutic for Sickle Cell Disease
- Beam Therapeutics to Present Data Highlighting Robust Manufacturing Process for BEAM-101 at 2024 European Hematology Association (EHA) Hybrid Congress
Earlier from Beam Therapeutics
- Beam Therapeutics Announces Appointment of Sravan Emany as Chief Financial Officer
- Beam Therapeutics Expands its Board of Directors with Appointment of Chirfi Guindo, Global Biopharma Strategy and Commercial Leader
- Beam Therapeutics to Participate in 2024 Jefferies London Healthcare Conference
- Beam Therapeutics Reports Third Quarter 2024 Financial Results and Progress Across Priority Programs
- Beam Therapeutics to Present Data Across Hematology Franchise, Including First Clinical Data for BEAM-101 in Sickle Cell Disease and ESCAPE Non-human Primate Data, at American Society of Hematology (ASH) Annual Meeting
Later from Beam Therapeutics
- Beam Therapeutics Presents New Non-human Primate (NHP) Data Demonstrating Proof-of-concept for ESCAPE, a Non-genotoxic, Antibody-based Conditioning Approach to Treating Sickle Cell Disease, at American Society of Hematology (ASH) Annual Meeting
- Beam Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference
- Beam Therapeutics Announces Progress in Hematology and Genetic Disease Franchises and Outlines Key 2025 Anticipated Catalysts
- Beam Therapeutics to Encore Data from BEACON Phase 1/2 Clinical Trial of BEAM-101 in Sickle Cell Disease at 2025 Tandem Meetings of ASTCT and CIBMTR
- Beam Therapeutics to Participate in Guggenheim SMID Cap Biotech Conference
Follow Beam Therapeutics into a list and get an email when it puts out news.
Follow Beam Therapeutics